Trial Profile
Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Exemestane
- Indications Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms ARB
- Sponsors Astellas Pharma Europe Ltd
- 10 Oct 2020 This trial has been discontinued in UK (Global End Date: 31 Mar 2020), according to European Clinical Trial Database record.
- 24 Feb 2020 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 24 Feb 2020 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.